Executive summary: Japanese guidelines for atopic dermatitis (ADGL) 2024

Hidehisa Saeki; Yukihiro Ohya; Hirokazu Arakawa; Susumu Ichiyama; Toshio Katsunuma; Norito Katoh; Akio Tanaka; Hideaki Tanizaki; Yuichiro Tsunemi; Takeshi Nakahara; Mizuho Nagao; Masami Narita; Michihiro Hide; Takao Fujisawa; Masaki Futamura; Koji Masuda; Tomoyo Matsubara; Hiroyuki Murota; Kiwako Yamamoto-Hanada; Junichi Furuta; Committee for Clinical Practice Guidelines for the Management of Atopic Dermatitis 2024; Japanese Society of Allergology; Japanese Dermatology Association

doi:10.1016/j.alit.2025.01.003

Executive summary: Japanese guidelines for atopic dermatitis (ADGL) 2024

Allergol Int. 2025 Apr;74(2):210-221. doi: 10.1016/j.alit.2025.01.003. Epub 2025 Feb 21.

Authors

Hidehisa Saeki¹, Yukihiro Ohya², Hirokazu Arakawa³, Susumu Ichiyama⁴, Toshio Katsunuma⁵, Norito Katoh⁶, Akio Tanaka⁷, Hideaki Tanizaki⁸, Yuichiro Tsunemi⁹, Takeshi Nakahara¹⁰, Mizuho Nagao¹¹, Masami Narita¹², Michihiro Hide¹³, Takao Fujisawa¹¹, Masaki Futamura¹⁴, Koji Masuda¹⁵, Tomoyo Matsubara¹⁶, Hiroyuki Murota¹⁷, Kiwako Yamamoto-Hanada¹⁸, Junichi Furuta¹⁹; Committee for Clinical Practice Guidelines for the Management of Atopic Dermatitis 2024; Japanese Society of Allergology; Japanese Dermatology Association

Affiliations

¹ Department of Dermatology, Nippon Medical School, Tokyo, Japan. Electronic address: h-saeki@nms.ac.jp.
² Department of Occupational and Environmental Health, Graduate School of Medical Sciences and Medical School, Nagoya City University, Nagoya, Japan.
³ Kitakanto Allergy Research Institute, Kibounoie Hospital, Gunma, Japan.
⁴ Department of Dermatology, Nippon Medical School, Tokyo, Japan.
⁵ Department of Pediatrics, The Jikei University Daisan Hospital, Tokyo, Japan.
⁶ North Campus of Kyoto Prefectural University of Medicine and Department for Medical Innovation and Translational Medical Science, Kyoto Prefectural University of Medicine Graduate School of Medical Science, Kyoto, Japan.
⁷ Department of Dermatology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
⁸ Department of Dermatology, Kansai Medical University, Osaka, Japan.
⁹ Department of Dermatology, Saitama Medical University, Saitama, Japan.
¹⁰ Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
¹¹ Allergy Center, National Hospital Organization Mie National Hospital, Tsu, Japan.
¹² Department of Pediatrics, Faculty of Medicine, Kyorin University, Tokyo, Japan.
¹³ Department of Dermatology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan; Department of Dermatology, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan.
¹⁴ Division of Pediatrics, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
¹⁵ Department of Dermatology, Kyoto Prefectural University of Medicine Graduate School of Medical Science, Kyoto, Japan.
¹⁶ Department of Pediatrics, Dokkyo Medical University Saitama Medical Center, Saitama, Japan.
¹⁷ Department of Dermatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
¹⁸ Allergy Center, National Center for Child Health and Development, Tokyo, Japan.
¹⁹ Medical Informatics and Management, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.

PMID: 39986987
DOI: 10.1016/j.alit.2025.01.003

Abstract

This is an abridged edition of English version of the Clinical Practice Guidelines for the Management of Atopic Dermatitis 2024. Atopic dermatitis (AD) is a disease characterized by relapsing eczema with pruritus as a primary lesion. A crucial aspect of AD treatment is the prompt induction of remission via the suppression of existing skin inflammation and pruritus. To achieve this, topical anti-inflammatory drugs such as topical corticosteroids, tacrolimus ointment, delgocitinib ointment, and difamilast ointment have been used. However, the following treatments should be considered in addition to topical therapy for patients with refractory moderate-to-severe AD: oral cyclosporine, subcutaneous injections of biologics (dupilumab, nemolizumab, tralokinumab), oral Janus kinase inhibitors (baricitinib, upadacitinib, abrocitinib), and phototherapy. In the revised guidelines, descriptions of five new drugs, namely, difamilast, nemolizumab, tralokinumab, upadacitinib, and abrocitinib, have been added. The guidelines present recommendations to review clinical research articles, evaluate the balance between the advantages and disadvantages of medical activities, and optimize medical activity-related patient outcomes with respect to several important points requiring decision-making in clinical practice.

Keywords: Atopic dermatitis; Clinical practice guidelines; Decision-making; Evidence-based medicine; Treatment.

Publication types

Practice Guideline

MeSH terms

Dermatitis, Atopic* / diagnosis
Dermatitis, Atopic* / drug therapy
Dermatitis, Atopic* / therapy
Disease Management
Humans
Janus Kinase Inhibitors / therapeutic use
Japan
Review Literature as Topic

Substances

Janus Kinase Inhibitors